ASX Runners of the Week: Killi, Amplia, NuEnergy, and 4D Medical Lead Market Surge
This week's Bulls N' Bears ASX Runner of the Week is Killi Resources, highlighting a diverse group of top performers amid fluctuating market conditions. The countdown is on for critical issues like fuel security and global energy disruptions, shaping investment landscapes.
Fuel Security and Market Dynamics
Australia faces a looming fuel security crisis, with reserves dwindling to just 34 days of petrol, 30 days of diesel, and 27 days of jet fuel. This situation stems from years of policy neglect, including ignoring warnings about refinery closures in favor of cheap Asian imports. Meanwhile, geopolitical events, such as potential Iran deals and Tropical Cyclone Narelle disrupting WA gas operations, add volatility to energy markets. The ASX rebounded 2.5% this week, buoyed by these factors and a new EU-Australia free trade agreement aimed at reducing reliance on Chinese critical minerals.
Killi Resources Ltd (ASX: KLI) – Up 304%
Killi Resources takes the top spot with a staggering 304% surge, driven by a corporate overhaul and strategic initiatives. The company appointed former Fortescue CEO Nev Power as non-executive chair, alongside consultants Steve Parsons and Michael Naylor, known for their success in resources deals. A $1.424 million capital raise further bolstered its position. Killi secured a Queensland government CEI grant for drilling at its Mt Rawdon West project, targeting gold-copper prospects like Mt Rawdon Fault and King Louie Breccia. With high-profile leadership and funded exploration, Killi is poised as an attractive early-stage story.
Amplia Therapeutics Ltd (ASX: ATX) – Up 144%
Amplia Therapeutics more than doubled its share price, fueled by promising clinical trial results for pancreatic cancer treatment. In its ACCENT trial, 5 out of 64 patients achieved a pathological complete response—no detectable cancer—a rare outcome in this aggressive disease with a 12.5% five-year survival rate. The therapy, narmafotinib, combined with other drugs, has shown unprecedented efficacy, with FDA registration already secured. As global demand for precision oncology grows, Amplia's breakthrough positions it as a leader in transforming cancer care.
NuEnergy Ltd (ASX: NGY) – Up 102%
NuEnergy gained 102%, attributed to speculation around its coal bed methane projects in Indonesia. The company, focused on domestic gas supply, saw its shares surge despite no official news, leading to an ASX trading halt. In a tight gas market exacerbated by events like Tropical Cyclone Narelle, NuEnergy's flagship Tanjung Enim project—Indonesia's first commercial-scale coalbed methane development—offers potential as a valuable future resource. Investors are betting on scarcity-driven value, with the stock up about 100% over the past year.
4D Medical Ltd (ASX: 4DX) – Up 76%
4D Medical rose 76% on news that the Mayo Clinic adopted its CT:VQ lung imaging technology. This non-contrast system provides ventilation-perfusion analysis from standard CT scans, offering a less invasive alternative to traditional methods. Mayo's endorsement, following deployments at other top US medical centers, strengthens 4DMedical's commercial pipeline. Compatible with existing hardware, the technology aims to become a next-generation standard in respiratory diagnostics, with shares up over 3,000% in eight months.
These runners reflect broader trends in resources, biotech, and energy, showcasing how strategic moves and market conditions drive ASX performance. For more updates, contact relevant sources.
